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Abstract
Background: Hodgkin lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL), are forms of malignant
lymphoma defined by unique morphologic, immunophenotypic, genotypic, and clinical characteristics, but both
overexpress CD30. We used sub-megabase resolution tiling (SMRT) array-based comparative genomic
hybridization to screen HL-derived cell lines (KMH2 and L428) and ALCL cell lines (DEL and SR-786) in order to
identify disease-associated gene copy number gains and losses.
Results: Significant copy number gains and losses were observed on several chromosomes in all four cell lines.
Assessment of copy number alterations with 26,819 DNA segments identified an average of 20 genetic alterations.
Of the recurrent minimally altered regions identified, 11 (55%) were within previously published regions of
chromosomal alterations in HL and ALCL cell lines while 9 (45%) were novel alterations not previously reported.
HL cell lines L428 and KMH2 shared gains in chromosome cytobands 2q23.1-q24.2, 7q32.2-q36.3, 9p21.3-p13.3,
12q13.13-q14.1, and losses in 13q12.13-q12.3, and 18q21.32-q23. ALCL cell lines SR-786 and DEL, showed gains
in cytobands 5p15.32-p14.3, 20p12.3-q13.11, and 20q13.2-q13.32. Both pairs of HL and ALCL cell lines showed
losses in 18q21.32-18q23.
Conclusion: This study is considered to be the first one describing HL and ALCL cell line genomes at sub-
megabase resolution. This high-resolution analysis allowed us to propose novel candidate target genes that could
potentially contribute to the pathogenesis of HL and ALCL. FISH was used to confirm the amplification of all three
isoforms of the trypsin gene (PRSS1/PRSS2/PRSS3) in KMH2 and L428 (HL) and DEL (ALCL) cell lines. These are
novel findings that have not been previously reported in the lymphoma literature, and opens up an entirely new
area of research that has not been previously associated with lymphoma biology. The findings raise interesting
possibilities about the role of signaling pathways triggered by membrane associated serine proteases in HL and
aggressive NHL, similar to those described in epithelial tumors.
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Background
Hodgkin lymphoma (HL) and Anaplastic Large Cell Lym-
phoma (ALCL), are forms of malignant lymphoma
defined by unique morphologic, immunophenotypic,
genotypic, and clinical characteristics, but both overex-
press CD30 [1,2], a 120 kDa member of the TNF/NGFR
family [3]. The aetiology and pathogenesis of these two
disorders are incompletely understood. Hodgkin's lym-
phoma (HL), one of the most common malignant lym-
phomas in young adults, was first described by Thomas
Hodgkin in 1832. The cellular composition of the tumor
tissue in HL consists of a small number (approximately
0.1% to 1%) of neoplastic Hodgkin and Reed-Sternberg
(HRS) cells surrounded by a sea of benign reactive cells of
diverse lineage, with or without dense sclerosis. Although
the molecular mechanisms that give rise to HRS cells
remain to be fully elucidated, it is now established that
such cells are derived from pre-apoptotic germinal centre
B cells which have lost much of the B-lineage-specific gene
expression [4,5].
Anaplastic large cell lymphoma (ALCL) is a type of non-
Hodgkin lymphoma seen in both adults and children.
Most cases are derived from T cells or "null" cells lacking
T or B phenotypic or genotypic lineage markers. Up to
75% of ALCL cases harbour the translocation (2;5)
(p23;q35) [6]. This translocation results in a fusion gene
containing the nucleophosmin gene (NPM) and a recep-
tor tyrosine kinase gene called anaplastic lymphoma
kinase (ALK). The NPM-ALK fusion gene codes for a con-
stitutively activated tyrosine kinase that behaves as an
oncogene. Several variant translocations and fusion genes
are now known. Anti-ALK antibodies can be used in for-
malin-fixed paraffin embedded tissue sections in order to
identify ALCL cases with t(2;5) or variant translocations.
Over 80% of paediatric ALCL and 30% of adult ALCL
express ALK. ALK+ cases tend to be in younger patients
with a better overall survival than ALK negative cases [7].
There are common morphological and/or phenotypic fea-
tures between classic Hodgkin lymphoma (cHL) and
some non-Hodgkin lymphoma (NHL), including primary
mediastinal B cell lymphoma, diffuse large B cell lym-
phoma, and ALCL [8]. The term Hodgkin's-like anaplastic
large cell lymphoma (HD-Like ALCL) was used in the
Revised European American lymphoma (REAL) classifica-
tion to describe borderline cases with features of both
ALCL and classical HL (cHL) [9,10]. The World Health
Organization (WHO) classification system does not rec-
ognise this category as an entity. For cases on the morpho-
logical borderline between HL and ALCL, the WHO
classification system states that the expression of CD15
without the expression of T-cell antigens favors HL,
whereas the absence of CD15 expression and the presence
of T-cell antigens favors ALCL [11]. The exact pathobio-
logic differences between these two types of lymphoma,
however, remain to be fully explained. To investigate
these common features between HL and ALCL, we under-
took a study of gene copy number alteration profiling of
these lymphomas using array-based submegabase resolu-
tion comparative genomic hybridization in 2 HL and 2
ALCL cell lines.
It is possible to directly identify genes involved in chro-
mosomal alterations in cell line model systems and then
rapidly explore their significance as potential diagnostic
and therapeutic targets and roles in human cancer pro-
gression. Comparative genomic hybridization (CGH) is a
technique that permits the detection of chromosomal
copy number changes without the need for cell culturing.
Conventional CGH uses metaphase chromosomes and
the method typically has a resolution of 10 Mb, suitable
for simple loss or gain assessments [12]. In array-CGH
well-defined arrayed sequences of DNA have replaced the
metaphase chromosomes as the hybridization targets on
glass slides [13]. This approach enables a quantitative
measure of gene copy number alterations at high resolu-
tion and uses in-silico analysis to map them accurately and
directly to chromosomal locations. Array-CGH is more
sensitive than conventional CGH because genomic DNA
arrays allow for the detection of several chromosomal
abnormalities that are missed by conventional CGH [14-
16]. Most recently, the whole human genome has been
arrayed as 26,819 bacterial artificial chromosome (BAC)
derived amplified fragment pools spotted in duplicate
(53,638 elements) resulting in a Sub-Megabase Resolu-
tion Tiling (SMRT)-set re-array array with complete cover-
age of the sequenced human genome [17]. This method
allows the detection of regions of loss or gain as small as
40–80 kb.
Previously published reports have used lower resolution
methods to identify chromosomal alterations that may be
involved in the pathogenesis of HL and/or ALCL. In the
current study, SMRT-array-based-CGH was used to screen
HL-derived cell lines (KMH2 and L428) and ALCL cell
lines (DEL and SR-786) to identify, at high resolution,
gene copy number alterations that may be involved in the
pathogenesis of HL and ALCL. Gene copy number gains
and losses were observed on several chromosomes in all
four cell lines investigated in this study. These alterations
not only confirmed previously published chromosomal
regional aberrations in HL and ALCL, but also defined 9
novel abnormal regions. We identified several regions of
amplification, many in loci not previously known to be
amplified. In order to develop a more detailed molecular
characterization of HL and ALCL cell lines, we used the
Ontario Cancer Institute (OCI) Human 27 k cDNA micro-
arrays to investigate genes differentially expressed in the
same four cell models of HL and ALCL, in comparison toMolecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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Universal Human Reference RNA (UHRR) [unpublished
data]. The gene expression profiles were then examined
for correlation with the gene copy number alterations
identified by SMRT array-based CGH.
Results
Gene copy number profiles of the four HL and ALCL cell 
lines
Gene copy number profiles of the four HL and ALCL cell
lines were created by co-hybridizing differentially labeled
sample DNA with reference male DNA on the a whole
genome tiling resolution array that contains 26,819 BAC-
derived amplified fragment pools spotted in duplicate.
The analysis of 53,638 data points for each of the four cell
lines facilitated the localization of altered chromosomal
regions to within single BAC clones and the subsequent
identification of genomic imbalances between regions.
Gene copy number gains and losses were observed on at
least 12 chromosomes in all four cell lines. Only those
alterations recurring in at least two of the four cell lines
were used to define minimally altered regions (MAR). A
summary of genomic alterations recurring in HL and
ALCL cell lines is shown in Table 1. These alterations
defined 9 novel regions not previously reported in the lit-
erature. HL cell lines L428 and KMH2 shared gains in
chromosome cytobands 2q23.1-q24.2, 7q32.2-q36.3,
9p21.3-p13.3, 12q13.13-q14.1, and losses in 13q12.13-
q12.3, and 18q21.32-q23. ALCL cell lines SR-786 and
DEL, showed gains in cytobands 5p15.32-p14.3,
20p12.3-q13.11, and 20q13.2-q13.32. Both pairs of HL
and ALCL cell lines showed losses in 18q21.32-q23. Addi-
tional abnormalities were seen in individual cell lines, but
were not common to both pairs of ALCL or HL cell lines.
Figure 1 shows the whole genomic array CGH SeeGH
karyogram of KMH2 cell line versus pooled normal male
genomic DNA.
Correlation of gene copy number alterations and gene 
expression profiles
In order to study the overall impact of gene copy number
alterations on gene expression, we analyzed the same four
cell lines using the Ontario Cancer Institute (OCI)
Human 27 k cDNA microarrays [unpublished data]. We
evaluated mean gene expression and variability within
array-based CGH altered regions and explored the correla-
tion between the copy number alterations of each gene
and its position within these regions as shown in Table 2.
Only 35% (138/395) of expressed genes showed correla-
tion with copy number alterations. Of these genes, 59%
showed strong correlation whereas 41% showed weak
correlation. These are similar to findings by other groups
who found that the expression of genes in the same
altered region correspond very differently to gain or loss
of genetic material depending not only on a given gene's
position but also on its regulation [18].
The genomic alterations recurring in HL and ALCL
We first investigated whether the identified MARs
included the chromosomal alterations previously
reported in HL and ALCL cell lines. The previously
reported regions that show chromosomal alterations are
shown in Table 2. Our data confirm previous results from
primary Hodgkin's tumors suggesting an important path-
ogenic role of MYC (8q24), REL (2p16) and JAK2 (9p24)
in HL [19]. Even in the case of previously identified
regions, the current study added further information
because most of the previous reported cases looked into
either HL or ALCL alone and also used lower resolution
methods. The current study has advantages over previous
studies because it used array-based CGH for both HL and
ALCL cell lines and, in addition, used the same cell lines
for gene expression in order to correlate those chromo-
somal copy number alterations with the gene expression
profiling. For example, Gogusev et al. [20] detected ampli-
cons on 1q21~q44 on the ALCL-derived DEL cell line as
shown in Table 2. In our current study, we could resolve
two specific regions; one on 1q25.2-q31.3 and the other
on 1q42.2-q43 that showed copy number gains in ALCL
cell lines (DEL and SR-786). 
The 1q25.2-q31.3 (17.73 Mb) gene-dense MAR of gain in
ALCL encompasses 68 Refseq annotated genes. Among
these, LHX4 (LIM homeobox 4) was found to be upregu-
lated in the HL and ALCL cell lines. There is no published
Table 1: Gains and Losses in HL ALCL cell lines
Cytoband KMH2 L428 DEL SR-786
1q25.2-q31.3 N N GG
1q42.2-q43 L N GG
2p16.2-p13.3 GG NN
2q23.1-q24.2 GG NN
2q24.2-q31.3 G G L N
5p15.32-p14.3 LN GG
5q14.1-q15 L L G N
7q11.1-q36.3 GG GN
8q23.3-24.12 GG NN
9p24.3-p24.1 GG NL
9p21.3-p12 GG NN
11q22.1-q23.3 L L N N
12q13.13-q14.1 GG NN
13q12.13-q12.3 LL GN
13q13.1-q21.32 L L N N
13q31.1-q34 L L N N
16q22.1-q24.1 GG NN
20p12.3-q13.11 L N GG
20q13.2-q13.32 L N GG
18q21.32-q23 LL LL
Novel regions are in underlined bold. L and G indicate losses and 
gains, respectively, in chromosomal regions in HL and ALCL cell 
lines, whereas N indicates no alteration was found.Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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information regarding the role of LHX4  in lymphoma
thus further analysis is required to determine the signifi-
cance of increased expression of LHX4 in HL and ALCL.
Recently, using quantitative real-time reverse-transcrip-
tion PCR, it was found that the LHX4 mRNA is expressed
at high levels in leukemic cells and in an acute lymphob-
lastic leukemia (ALL) cell line [21]. In addition to the
LHX4 gene, other candidate genes located along the chro-
mosomal region 1q25.2-q31.3, such as PNF2, NEK7 and
PCTRK3, could also be involved in ALCL pathogenesis.
The other previously reported region is the amplified MAR
on 2q, spanning 18.76 Mb, containing 81 Refseq anno-
tated genes. Our study identified MTX2 (Metaxin 2) as a
highly expressed gene. MTX2 was found to be differen-
tially overexpressed in HL cell lines compared to ALCL cell
lines.
The 13q12.3-q12.3 (5.49 Mb) gene-dense MAR of gain in
DEL cell line and loss in HL encompasses 25 Refseq anno-
tated genes. Among these GTF3A (General transcription
factor IIIA) was found to be upregulated in HL in compar-
ison to ALCL cell lines. There is no published information
regarding the role of GTF3A in lymphoma, therefore fur-
ther analysis is required to determine the significance of
GTF3A in HL and ALCL. A recent study identified GTF3A
as down-regulated in Down syndrome leukocytes in com-
parison to normal controls [22], which might implicate
GTF3A dysfunction in Down syndrome-associated acute
myeloid leukemia.
Whole genome SMRT aCGH SeeGH karyogram of KMH2 cell line versus pooled normal male genomic DNA Figure 1
Whole genome SMRT aCGH SeeGH karyogram of KMH2 cell line versus pooled normal male genomic DNA. 
Each dot represents data from one BAC derived segment on the array. Data points to left and right of center purple line rep-
resent genetic losses and gains, respectively.Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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The MAR 2q23.1-q24.2 (13.83 Mb) seems to be a region
of gain in HL and it encompasses 40 Refseq annotated
genes. Among these are TNFAIP6, also known as TSG6
(tumor necrosis factor, alpha-induced protein 6), LY75
(Lymphocyte antigen 75), SLC25A12 (Solute carrier fam-
ily 25 (mitochondrial carrier, Aralar), member 12), and
GCA  (Grancalcin, EF-hand calcium binding protein).
TNFAIP6, LY75, SLC25A12 and GCA were found to be dif-
ferentially up-regulated in HL in comparison to ALCL cell
lines. TSG-6 protein is known to form a complex with
inter-alpha-inhibitor (IalphaI), a potent serine protease
inhibitor, which may be immobilized via the hyaluronan
(HA)-binding domain of TSG-6 protein in the HA-rich
extracellular matrix of cartilage [23]. It is suggested that
this mechanism might protect cartilage from extensive
degradation even in the presence of acute inflammation.
Further analysis is required to investigate the role of
TNFAIP6/TSG-6, LY75, SLC25A12, and GCA in HL and
ALCL pathogenesis. The 20p13.2-q13.32 (6.95 Mb) gene-
dense MAR of gain in ALCL and loss in HL encompasses
31 Refseq annotated genes. Among these, PCNA (Prolifer-
ating cell nuclear antigen) and FKBP1A (FK506 binding
Table 2: Gains and Losses of the regions and the genes reported to be differentiallyexpressed.
Cytoband Size (Mb) Minimal region 
boundary clones
Number of refseq 
genes in region
Reported Copy 
number alterations
Genes known/found to be 
differentially expressed
1q25.2-q31.3 17.73 174994286–
192721998
68 Gogusev et al. (2002) ANGPTL1, LHX4, PNF2, RGS1, 
NEK7, PCTRK3, CTSE, MYOG, 
RGS2
1q42.2-q43 9.16 228621517–
237777167
30 Gogusev et al. (2002) LGALS8, NID, MTR, OPN3, GNG4, 
TBCE
2p16.2-p13.3 17.77 53587332–70354068 63 Joos et al. (2002) REL, PNPT1, RPS27A, XPO1, 
SLC1A4, MSH6, MGC15407
2q23.1-q24.2 13.83 149314143–
163139362
40 current study TNFAIP6, GCA, LY75, 
SLC25A12, DCL-1, ITGB6, RBMS1
2q24.2-q31.3 18.76 163139362–
181903843
81 Franke et al. (2001) MTX2, DPP4, ATP5G3, TLK1, 
STAT1, BBS5, SCRN3, NFE2L2
5p15.32-p14.3 10 5257164–15261389 20 current study DNAH5, DDX4, MGC5309, 
ARFRP2, CTNND2, MYO10
5q14.1-q15 18.99 79623141–98609560 48 Joos et al. (2003) C5ORF12, CACH-1, RPS23, ANKRD32, 
TBCA, KIAA0372, RHOBTB3
7q11.1-q36.3 97.02 61369644–158387760 575 current study PRSS1, TRY6, PRSS2, CDK6, 
CLDN4, HSPB1, HGF, mTERF, 
ING3, TPST1
8q23.3-24.12 5.08 116154379–
121233686
19 Joos et al. (2003) MYC, RAD21, DEPDC6, THRAP6, 
DCC1
9p24.3-p24.1 5.9 23994–5928516 28 Joos et al. (2003) JAK2, RANBP6, UHRF2, C9orf46, 
C9orf123, MLANA, RCL1, AK3L1
9p21.3-p12 14.87 25192411–40063723 119 current study PRSS3, DNAJA1, RPS6, CCDC2
11q22.1-q23.3 19.91 98410656–118317962 106 Falzetti et al. (1999) ATM, DDX6, CRYAB, PDGFD
12q13.13-q14.1 8.64 53812697–62450135 114 current study DDIT3, DTX3, KRT6IRS, 
HOXC4, HOXC5, LEMD3, 
TBK1, USP15
13q12.13-q12.3 5.49 25577047–31063440 25 current study GTF3A, MTIF3, PAN3, APRIN, BRCA2
13q13.1-q21.32 35.16 31151386–66311960 108 Joos et al. (2002) Ufm1, C13orf1, RCBTB1, KBTBD6, 
NARG1L, DDX26, NUDT15
13q31.1-q34 27.91 86156309–114062150 74 Joos et al. (2002) STK24, DCT, GPC5, DZI, EFNB2, 
TM9SF2, RASA3, LOC196541
16q22.1-q24.1 19.68 65582104–85259588 170 Joos et al. (2002) CIRH1A, CKLFSF3, DNCL12, 
BMO39
20p12.3-q13.11 33.93 8872139–42799402 185 current study PCNA, SNAP25, FKBP1A, 
SNPH, TH1L, SPAG4L, TDE1, 
SLC2A10, C20orf52, EYA2
20q13.2-q13.32 6.95 50997916–57946927 31 current study TFAP2C, CDH4, ZFP64, GNAS, 
ATP5E
18q21.32-q23 19.03 58644127–77673453 52 current study VPS4B, RTTN, PIGN, ZCCHC2, 
BCL2, FLJ25715, TXNL4A, ZNF516, 
PARD6G
Aligned with data from the University of California, Santa Cruz Human Browser April 2003 Freeze. Novel regions are in underlined bold. Genes in 
italic and underlined are those that previously been reported {Joos et al. 2003 [19]; Gogusev et al. [20]; Joos et al. 2002 [29]; Franke et al. [54]; 
Falzetti et al. [55]}, whereas those in bold and italic are those found to be over-expressed and down regulated, respectively, in the current study. Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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protein 1A, 12 kDa) were found to be up-regulated in
ALCL and HL cell lines.
The 7q11.1-q36.3 (97.02 Mb) gene-dense MAR of gain in
HL and DEL cell lines encompasses 575 Refseq annotated
genes. Among these are CDK6 (Cyclin-dependent kinase
6), PRSS1 (Protease, serine, 1 (trypsin 1)), PRSS2 (Pro-
tease, serine, 2 (trypsin 2)), CLDN4 (Claudin 4), HSPB1
(Heat shock 27 kDa protein 1), and HGF (Hepatocyte
growth factor (hepapoietin A; scatter factor)). PRSS1,
PRSS2 and HSPB1 were found to be overexpressed in HL
cell lines, whereas CLDN4 was found to be overexpressed
in both HL and ALCL cell lines. CDK6 and HGF were
found to be overexpressed in the 2 HL cell lines and in the
DEL (ALCL) cell line. Further study will obviously be
essential to validate the CDK6, HSPB1, PRSS1,  PRSS2,
HGF, and CLDN4 expression at the protein level in HL
and ALCL.
Chromosomes 7 and 9 showed amplification of isoforms
of the trypsin gene in the KMH2 (7q32.2-q36.3), L428
(7q34-q35) and DEL (7q11.1-q36.3) cell lines but not in
SR-786 in the case of PRSS1/PRSS2, whereas PRSS3
showed amplification in HL cell lines (KMH2 at 9p21.1-
p13.3 and L428 at 9p21.1-p12) but not in ALCL cell lines
as shown in Figures 2 and 3. These findings were con-
firmed by FISH analysis as shown in Figure 4. These are
novel findings that have not been previously reported in
the lymphoma literature, and opens up an entirely new
area of research that has not been associated with lym-
phoma biology. The observations raise interesting possi-
bilities about the role of signaling pathways triggered by
membrane associated serine proteases in HL and ALCL,
similar to those implicated in epithelial tumors [24]. Con-
firmation of these findings could lead to novel therapeutic
approaches in HL and NHL.
Pathway mapping of the genes reported to be 
differentially expressed in HL and ALCL cell lines
The list of the 137 genes we found to be differentially
expressed in HL and ALCL cell lines (Table 2) were sub-
jected to the Pathway-Express (PE) software [25]. PE gen-
erates a list of pathways that the submitted genes are
involved in, complete with a p-value for each pathway,
indicating the relative importance of each. After generat-
ing a list of pathways for the submitted list of genes from
the Onto-Tools database, PE first calculates a perturbation
factor PF (g) for each input gene. The PF takes into
account the (i) normalized fold change of the gene and
(ii) the number and amount of perturbation of genes
downstream from it [26]. Fifty of these 137 deregulated
genes in HL and ALCL were found to represent 12 main
different pathways (Figure 5). Of these, pathways that
included only 1 gene, were grouped together in the "oth-
ers" category (38%). Genes involved in colorectal cancer
were represented and corresponded to 10% of the total
number of deregulated genes. Eight % of the genes are
involved in encoding focal adhesion proteins and 6% of
the genes are involved in the MAPK signaling pathway.
We also found that 6% of the genes are involved in Jak/
STAT signaling pathway, 6% in the cell cycle, 6% in Toll-
Genomic profiles of chromosome 9 for the cell lines KMH2, L428, DEL and SR-786 Figure 2
Genomic profiles of chromosome 9 for the cell lines KMH2, L428, DEL and SR-786. Data points to left and right of 
center purple line represents genetic losses and gains in the above mentioned cell lines. Green and red lines are scale bars at 
log2 ratios of -1.0 and 1.0 respectively.Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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like receptor signaling, 4% in encoding cell adhesion mol-
ecules and 4% in apoptosis.
Functional profiling of the genes reported to be 
differentially expressed in HL and ALCL cell lines
The list of the 137 genes reported to be differentially
expressed in HL and ALCL cell lines (Table 2) were also
subjected to the Onto-Express (OE) software [27]. OE can
be used to organize the list of differentially regulated
genes into groups, allowing a better understanding of the
underlying biological functions through the use of Gene
Ontology (GO) database, complete with a p-value for
each functional profile indicating the relative importance
of each. A comprehensive list of these functional groups
including a list of all genes can be found in [see Additional
file 1].
Discussion
Chromosomal aberrations can be studied using many dif-
ferent techniques, such as Comparative Genomic Hybrid-
ization (CGH), Fluorescence in Situ Hybridization
(FISH), and Representational Difference Analysis (RDA).
Although chromosome CGH quickly became a standard
method for cytogenetic studies, technical limitations
restrict its usefulness as a comprehensive screening tool.
Recently, the resolution of Comparative Genomic Hybrid-
izations has been greatly improved using microarray tech-
nology. Substitution of the chromosome targets by a
matrix consisting of an ordered set of defined nucleic acid
target sequences greatly enhances the resolution and sim-
plifies the analysis procedure, both of which are prerequi-
sites for a broad application of CGH as a research and
diagnostic tool. Array CGH has provided significant con-
tributions to our understanding of chromosomal changes
associated with tumor development and progression,
making it possible to detect 40–80 kb regions of chromo-
somal gain and loss covering the entire human genome in
a single experiment [28].
The genetic alterations involved in the pathogenesis of HL
are still largely unknown. HRS cells in most if not all cases
show numerical chromosome aberrations, as well as
amplifications and deletions of chromosomal sub-regions
[29,30]. Several recurrent chromosomal alterations have
been previously described but for most of these, identifi-
cation of the relevant genes is still pending [29,31].
Genomic profiles of chromosome 7 for the cell lines KMH2, L428, DEL and SR-786 Figure 3
Genomic profiles of chromosome 7 for the cell lines KMH2, L428, DEL and SR-786. Data points to left and right of 
center purple line represents genetic losses and gains in the above mentioned cell lines. Green and red lines are scale bars at 
log2 ratios of -1.0 and 1.0 respectively.Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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Recently, Kluiver et al. performed serial analysis of gene
expression (SAGE) and array-based comparative genomic
hybridization (aCGH) to identify genes involved in the
pathogenesis of classical Hodgkin lymphoma (cHL) [32].
The comparison of SAGE libraries of cHL cell lines L428
and L1236 with those of germinal centre B cells revealed
consistent overexpression of only 14 genes. In contrast,
141 genes were downregulated in both cHL cell lines,
including many B cell and HLA genes and aCGH revealed
gain of 2p, 7p, 9p, 11q and Xq and loss of 4q and 11q
[32].
We studied tumor cell lines derived from HL and ALCL
rather than primary lymphoma samples for the following
reasons. Primary lymphomas are heterogeneous, with var-
ying components such as infiltrating lymphocytes, invad-
ing blood vessels, and other stromal components which
contribute to the extracted DNA and RNA and thus mask
the signature of the neoplastic cells. The use of cell lines
avoids the problem of having heterogeneous populations
of cells complicating the analysis of the hybridization sig-
nals. Moreover, most of these cell lines preserve the phe-
notypic and differentiation related characteristics of
lymphoma. Array-based-CGH was used to screen HL-
derived cell lines (KMH2 and L428) and ALCL cell lines
(DEL and SR-786) to identify chromosomal region gains
and losses and gene copy number alterations that may
reveal genes involved in the pathogenesis of HL and
ALCL. Gene copy number gains and losses were observed
on at least 12 chromosomes in all four cell lines investi-
gated in this study. Assessment of copy number altera-
tions with 26,819 DNA segments identified an average of
20 genetic alterations. These alterations defined 9 (45%)
novel abnormal regions not previously reported in the lit-
erature. These novel regions may require further investiga-
tion in normal and tumor samples to eliminate the
possibility of copy number variations within the normal
human population. Of the recurrent MARs identified, 11
(55%) were identical to those determined in previously
published studies of genetic alterations using lower reso-
Locus-specific FISH validation of genetic copy number alterations for Trypsin gene Figure 4
Locus-specific FISH validation of genetic copy number alterations for Trypsin gene. (A) Locus-specific FISH of 
9p21.1-p12 amplification in KHM2 cell line. (B) Locus-specific FISH of 7q32.2-q36.3 non-amplification in SR-786 cell line. 
Orange and green signals indicate loci of spectrum orange and spectrum green labeled FISH probes, respectively.Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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lution CGH methods than the sub-megabase resolution
array-based CGH used in the current study.
The alterations in the main pathways responsible for con-
trolling the cell cycle in HL have rarely been studied and
poorly understood, mainly because the techniques used
for molecular studies in this disease have been limited by
the scarcity of malignant cells of interest [33]. The analysis
of cell-cycle regulation in different types of lymphoid and
epithelial neoplasms reveals a relationship whereby
increased clinical aggressiveness is associated with the
accumulation of genetic and epigenetic alterations [34].
In the current study, 3.6% of the genes reported to be dif-
ferentially expressed in HL and ALCL cell lines were
involved in cell cycle pathways. These include CDK6,
PCNA, and ATM.
The mitogen-activated protein kinases (MAPKs) (also
called extracellular signal-regulated kinase [ERK]) are a
group of protein serine/threonine kinases that are acti-
vated in response to a variety of extracellular stimuli and
mediate signal transduction from the cell surface to the
nucleus [35,36]. Zheng et al. [37] reported that the active
phosphorylated form of MAPK/ERK is aberrantly
expressed in cultured and primary HD cells. In the current
study, 3.6% of the genes were found to represent the
MAPK signaling pathway. These are DDIT3, HSPB1 and
MYC. Recently it was reported that Myxoid/round cell
liposarcoma (MLS/RCLS) may develop from cell types
other than preadipocytes because the fusion oncogene
FUS-DDIT3 and the normal DDIT3 induce a liposarcoma
phenotype when expressed in a primitive sarcoma cell
line [38]. The MLS/RCLS oncogene FUS-DDIT3  is the
result of a translocation derived gene fusion between the
splicing factor FUS and DDIT3. DDIT3 and FUS-DDIT3
show opposing transcriptional regulation of IL8 and sug-
gest that FUS-DDIT3 may affect the synergistic activation
of promoters regulated by the CCAAT/enhancer binding
protein (C/EBP) beta and NFkappaB [39].
Certain (2.4%) of the genes were found to be involved in
encoding tight junction proteins. These include CLDN4,
PARD6G. The claudin (CLDN) genes encode a family of
proteins important in tight junction formation and func-
tion [40]. Recently, it was reported that CLDN, and
CLDN4  are elevated in several epithelial malignancies
such as those originating from the pancreas, bladder, thy-
roid, fallopian tubes, ovary, colon, breast, uterus, and
prostate [40]. Surprisingly, our data showed overexpres-
sion of CLDN4 in HL and ALCL. The finding of expression
of these claudins in other tumors warrant further investi-
gation for CLD4 as well as other claudins in HL and ALCL
pathogenesis.
Another 3.6% of the genes were determined to be
involved in the Jak/STAT signaling pathway. These
include STAT1, JAK2 and MYC. The STAT proteins (Signal
Transducers and Activators of Transcription), were identi-
fied in the last decade as transcription factors which are
critical in mediating virtually all cytokine driven signaling
[41]. Several members of the STAT family of transcription
factors, namely STAT3, STAT5 and STAT6, are frequently
activated in HRS cells [42,43]. STATs can be activated by
cytokine receptors via the JAK kinases, by receptor tyro-
sine kinases (RTKs) and by 7 transmembrane receptors
[44]. In normal cells and in animals, ligand dependent
activation of the STATs is a transient process, lasting for
several minutes to several hours. In contrast, in many can-
cerous cell lines and tumors, where growth factor dysreg-
ulation is frequently at the heart of cellular
transformation, the STAT proteins (in particular Stats 1, 3
and 5) are persistently tyrosine phosphorylated or acti-
vated [45]. STATs can be divided into two groups accord-
ing to their specific functions [46]. One is made up of
STAT2, STAT4, and STAT6, which are activated by a small
number of cytokines and play a distinct role in the devel-
opment of T-cells and in IFN signaling [46]. The other
group includes STAT1, STAT3, and STAT5, activated in dif-
ferent tissues by means of a series of ligands and involved
in IFN signaling, development of the mammary gland,
response to GH, and embryogenesis [46]. This latter
group of STATS plays an important role in controlling cell-
cycle progression and apoptosis and thus contributes to
oncogenesis. Although increased expression of STAT1 has
been observed in many human neoplasia, this molecule
can be considered a potential tumor suppressor, since it
plays an important role in growth arrest and in promoting
apoptosis [46]. On the other hand, STAT3 and 5 are con-
sidered to be oncogenes, since they bring about the activa-
Pathways of the differentially expressed genes in HL-derived  and ALCL-derived cell lines Figure 5
Pathways of the differentially expressed genes in HL-derived 
and ALCL-derived cell lines.Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
Page 10 of 13
(page number not for citation purposes)
tion of cyclin D1, c-Myc, and bcl-xl expression, and are
involved in promoting cell-cycle progression, cellular
transformation, and in preventing apoptosis. Recently,
Cochet et al. reported that aberrant STAT activation in
Hodgkin cells may promote cell survival and, as a conse-
quence, facilitate oncogenic transformation [47].
Another interesting gene reported in this study is ING3
(inhibitor of growth family, member 3). The overexpres-
sion of ING3 was found to correlate with the gene copy
number alterations at 7q11.1-q36.3 in HL cell lines
(KMH2 and L428) and ALCL cell line (DEL) as shown in
Table 1 and 2. The novel ING tumor-suppressor family
proteins (ING1-5) have been recognized as the regulators
of transcription, cell cycle checkpoints, DNA repair, apop-
tosis, cellular senescence, angiogenesis, and nuclear phos-
phoinositide signaling [48]. Using stable clones of
melanoma cells overexpressing ING3, Wang et al. showed
that overexpression of ING3 significantly promoted UV-
induced apoptosis [48]. As there is no information
reported in the literature about ING3 in HL and ALCL, fur-
ther investigation is required to study the role of ING3 in
HL and ALCL pathogenesis.
The use of the gene expression profiling of the same four
cell lines used for array-based CGH proved to be useful in
identifying differentially expressed genes in those chro-
mosomal regions showing gene copy number alterations.
A search for the involved genes located in these chromo-
somal regions can potentially shed light on the molecular
pathogenesis of HL and ALCL. Our study found that dif-
ferent genes in the same altered region correspond very
differently to gain and loss of genetic material, probably
because of transcriptional regulation of each gene. A
recent study compared gene expression levels with copy
number alternations reported that gain of 2p and 9p did
not result in overexpression of the proposed target genes
c-REL and JAK2, but gain of two newly identified smallest
region of overlap (SROs) on 7p and Xq did correlate with
overexpression of FSCN1 and IRAK1 [32].
As can be seen from above (table 2), some of the genes in
this study were previously reported to be involved in path-
ways of HL and ALCL pathogenesis. On the other hand,
we propose that further analysis is required to investigate
the role of overexpression of the other deregulated genes
we have identified, that were not previously reported to be
dysregulated in HL and ALCL.
Conclusion
We used sub-megabase resolution tiling array-based com-
parative genomic hybridization to screen HL-derived cell
lines (KMH2 and L428) and ALCL cell lines (DEL and SR-
786) to identify disease-associated gene copy number
gains and losses. We identified 9 novel alterations in
regions not previously reported. This study is considered
to be the first one in describing HL and ALCL cell line
genomes at sub-megabase resolution. This high-resolu-
tion analysis allowed us to propose novel candidate genes
that could potentially contribute to the pathogenesis of
HL and ALCL. FISH was used to confirm the amplification
of all three isoforms of the trypsin gene (PRSS1/PRSS2/
PRSS3) in HL and DEL cell lines. These are novel findings
that have not been previously reported in the lymphoma
literature, and opens up an entirely new field of research
that has not been associated with lymphoma biology. Our
findings raise interesting possibilities about the role of sig-
naling pathways triggered by membrane associated serine
proteases in the pathogenesis of HL and aggressive NHL,
similar to those implicated in epithelial tumors. Future
validation studies on the copy number changes of the rel-
evant genes in the 9 novel regions, gene expression and
the protein expression levels in primary lymphoma tumor
tissue are needed to verify our results and to identify new
mechanisms in the pathogenesis of lymphomas and as
potential new diagnostic and prognostic biomarkers.
Methods
Cell lines, Cell Culture conditions and DNA extraction
The human HL-derived cell lines KM-H2, L-428 and the
ALCL cell lines DEL and SR-786 were obtained from the
Deutsche ammlung von Mikrooganism und Zellkulturen
GmbH (Braunschweig, Germany). All cell lines were cul-
tured in RPMI 1640 supplemented with 10% heat-inacti-
vated fetal bovine serum (Cansera Inc., Etiobicoke, ON,
Canada), L-glutamine and penicillin and streptomycin in
a humid environment of 5% CO2 at 37°C to a density of
106 cells/ml. Genomic DNA was extracted via standard
proteinase K/RNAse treatment and phenol-chloroform
extraction.
Array CGH
Tiling path array comparative genomic hybridization was
performed with a slight modification to the method
described previously [49-51]. Briefly, 200 ng of test and
reference DNA were separately labeled with Cyanine3-
dCTP and Cyanine5-dCTP (Perkin Elmer Life Sciences
Inc., Boston, MA, USA), respectively, via random priming
at 37°C for 16–18 h in the dark. Labeled sample and ref-
erence DNA probes were combined, precipitated, re-sus-
pended, blocked and hybridized onto BAC arrays
containing 26,819 clones spotted in duplicate on a single
slide. After hybridization, arrays were washed, rinsed, and
dried using an oil free air stream. Slides were scanned
using a charge-coupled device (CCD) based imaging sys-
tem (arrayWoRx eAuto, Applied Precision, Issaquah, WA,
USA). Images were analyzed using SoftWoRx Tracker Spot
Analysis software (Applied Precision). The ratios were
normalized using a stepwise normalization techniqueMolecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
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[52] to remove any biases added from non-biological
sources.
Custom software (SeeGH) was used to visualize normal-
ized data as log2 ratio plots. Genomic alterations were
classified as homozygous deletions, loss, normal, gain,
and amplification for ratios < -1.0, -1.0 to -0.15, -0.15 to
0.15, 0.15 to 1.0, and >1.0 respectively as previously
described [50].
Fluorescence in situ hybridization (FISH)
Bacterial artificial chromosome (BAC) clones N0520H11
and N0075N03 for PRSS1/2 and PRSS3, respectively, were
obtained from Dr. Wan L. Lam at the BC Cancer Research
Centre, Vancouver, BC, Canada. BAC DNA isolation was
carried out using the standard laboratory method of rapid
alkaline lysis maxipreparation. The chromosome 7 and 9
a-satellite plasmids and BAC DNA were labeled directly
with SpectrumGreen-dUTP® and SpectrumOrange-dUTP®
(Vysis, Downers Grove, IL, USA), respectively, using the
Vysis nick translation kit (Vysis) in accordance with the
manufacturer's instructions. Slide preparations of the cell
lines were fixed using methanol:acetic acid (3:1), and
dual-color FISH was performed. The labeled slides were
counterstained with 4', 6-diamidino-2-phenylindole
(DAPI; Sigma), mounted with antifade (Vysis), and stored
at -20°C. At least 100 nuclei were evaluated in each sam-
ple. For all slides, FISH signals and patterns were detected
using a Zeiss Axioplan Fluorescence microscope. Signals
were scored manually and images were captured using
Metasystems Isis FISH imaging software (MetaSystems
Group, Inc. Belmont, MA). The analysis of trypsin gene
amplification was conducted by counting the number of
probe signals within 100 cells and calculating the average
probe signals per cell. A ratio ≥ 2.0 of the probe signal to
chromosome 7 in case of PRSS1/PRSS2 and chromosome
9 in case of PRSS3 was considered as positive for amplifi-
cation using the criteria reported previously [53].
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors have read and approved the final version of
the manuscript.
FF participated in the design of the study, participated in
the array-CGH experiments, carried out the FISH analysis,
interpreted the results, and prepared the manuscript. MZ
contributed to the scientific discussion and manuscript
preparation. RL carried out the array-CGH analysis, inter-
preted the results, and contributed to manuscript prepara-
tion. ND participated in array-CGH data analysis. KH
participated in the FISH studies. DH contributed to FISH
analysis, scientific discussion and manuscript prepara-
tion. WL participated in the design of the study, provided
the array-CGH, and contributed in the preparation of the
manuscript. DB participated in the design of the study and
was responsible for its coordination, interpreted the
results independently of the author 1, and contributed in
the preparation of the manuscript.
Additional material
Acknowledgements
The authors would like to thank the Lam Lab Array CGH group for array 
production and Lindsey Kimm for technical assistance with array CGH 
experiments. This work was supported by grants from the Lymphoma 
Research Foundation of Canada and the Canadian Institutes of Health 
Research (CIHR).
References
1. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molec-
ular cloning and expression of a new member of the nerve
growth factor receptor family that is characteristic for
Hodgkin's disease.  Cell 1992, 68(3):421-427.
2. Vecchi V, Burnelli R, Pileri S, Rosito P, Sabattini E, Civino A, Pericoli
R, Paolucci G: Anaplastic large cell lymphoma (Ki-1+/CD30+)
in childhood.  Med Pediatr Oncol 1993, 21(6):402-410.
3. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson
CB: CD30 contains two binding sites with different specifici-
ties for members of the tumor necrosis factor receptor-asso-
ciated factor family of signal transducing proteins.  J Biol Chem
1996, 271(22):12852-12858.
4. Kuppers R, Hansmann ML: The Hodgkin and Reed/Sternberg
cell.  Int J Biochem Cell Biol 2005, 37(3):511-517.
5. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V,
Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R: Loss of the
B-lineage-specific gene expression program in Hodgkin and
Reed-Sternberg cells of Hodgkin lymphoma.  Blood 2003,
101(4):1505-1512.
6. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look
AT, Saltman DL: Fusion of a kinase gene, ALK, to a nucleolar
protein gene, NPM, in non-Hodgkin's lymphoma.  Science
1994, 263(5151):1281-1284.
7. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG:
Pathobiology of NPM-ALK and variant fusion genes in ana-
plastic large cell lymphoma and other lymphomas.  Leukemia
2000, 14(9):1533-1559.
8. Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska
I, De Wolf-Peeters C: Relationship between classic Hodgkin
lymphoma and overlapping large cell lymphoma investi-
gated by comparative expressed sequence hybridization
expression profiling.  J Pathol 2006, 210(2):155-162.
9. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G,
De Wolf-Peeters C, Falini B, Gatter KC, et al.: A revised European-
American classification of lymphoid neoplasms: a proposal
from the International Lymphoma Study Group.  Blood 1994,
84(5):1361-1392.
Additional file 1
A comprehensive list of the functional profiling of the genes. The data pro-
vided represent the functional profiling of the genes reported to be differ-
entially expressed in HL and ALCL cell lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-2-S1.pdf]Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
Page 12 of 13
(page number not for citation purposes)
10. Jaffe ES, Krenacs L, Raffeld M: Classification of T-cell and NK-cell
neoplasms based on the REAL classification.  Ann Oncol 1997,
8(Suppl 2):17-24.
11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Var-
diman J, Lister TA, Bloomfield CD: World Health Organization
classification of neoplastic diseases of the hematopoietic and
lymphoid tissues: report of the Clinical Advisory Committee
meeting-Airlie House, Virginia, November 1997.  J Clin Oncol
1999, 17(12):3835-3849.
12. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Wald-
man F, Pinkel D: Comparative genomic hybridization for
molecular cytogenetic analysis of solid tumors.  Science 1992,
258(5083):818-821.
13. Hughes S, Beheshti B, Marrano P, Lim G, Squire JA: Comparative
Genomic Hybridisation Analysis using Metaphase or Micro-
array Slides.   [http://www.utoronto.ca/cancyto/Books/
CGH_analysis.pdf].
14. Wessendorf S, Schwaenen C, Kohlhammer H, Kienle D, Wrobel G,
Barth TF, Nessling M, Moller P, Dohner H, Lichter P, Bentz M: Hid-
den gene amplifications in aggressive B-cell non-Hodgkin
lymphomas detected by microarray-based comparative
genomic hybridization.  Oncogene 2003, 22(9):1425-1429.
15. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A,
Dohner H, Cremer T, Lichter P: Matrix-based comparative
genomic hybridization: biochips to screen for genomic
imbalances.  Genes Chromosomes Cancer 1997, 20:399-407.
16. Hui AB, Lo KW, Teo PM, To KF, Huang DP: Genome wide detec-
tion of oncogene amplifications in nasopharyngeal carci-
noma by array based comparative genomic hybridization.  Int
J Oncol 2002, 20(3):467-473.
17. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP,
Snijders A, Albertson DG, Pinkel D, Marra MA, et al.: A tiling reso-
lution DNA microarray with complete coverage of the
human genome.  Nat Genet 2004, 36(3):299-303.
18. Melendez B, Diaz-Uriarte R, Cuadros M, Martinez-Ramirez A, Fern-
andez-Piqueras J, Dopazo A, Cigudosa JC, Rivas C, Dopazo J, Mar-
tinez-Delgado B, Benitez J: Gene expression analysis of
chromosomal regions with gain or loss of genetic material
detected by comparative genomic hybridization.  Genes Chro-
mosomes Cancer 2004, 41(4):353-365.
19. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-
Subero JI, Wolf J, Adamowicz M, Barth TF, Lichter P, Jauch A: Hodg-
kin's lymphoma cell lines are characterized by frequent
aberrations on chromosomes 2p and 9p including REL and
JAK2.  Int J Cancer 2003, 103(4):489-495.
20. Gogusev J, Telvi L, Nezelof C: Molecular cytogenetic aberrations
in CD30+ anaplastic large cell lymphoma cell lines.  Cancer
Genet Cytogenet 2002, 138(2):95-101.
21. Yamaguchi M, Yamamoto K, Miura O: Aberrant expression of the
LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in
chronic myelogenous leukemia in biphenotypic blast crisis.
Genes Chromosomes Cancer 2003, 38(3):269-273.
22. Malago W Jr, Sommer CA, Del Cistia Andrade C, Soares-Costa A,
Abrao Possik P, Cassago A, Santejo Silveira HC, Henrique-Silva F:
Gene expression profile of human Down syndrome leuko-
cytes.  Croat Med J 2005, 46(4):647-656.
23. Glant TT, Kamath RV, Bardos T, Gal I, Szanto S, Murad YM, Sandy JD,
Mort JS, Roughley PJ, Mikecz K: Cartilage-specific constitutive
expression of TSG-6 protein (product of tumor necrosis fac-
tor alpha-stimulated gene 6) provides a chondroprotective,
but not antiinflammatory, effect in antigen-induced arthritis.
Arthritis Rheum 2002, 46:2207-2218.
24. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE,
Maquoi E, Cataldo D, Foidart JM: Membrane associated pro-
teases and their inhibitors in tumour angiogenesis.  J Clin
Pathol 2004, 57(6):577-584.
25. Pathway-Express (PE) software   [http://vortex.cs.wayne.edu/
Projects.htm#Pathway-Express]
26. Khatri P, Sellamuthu S, Malhotra P, Amin K, Done A, Draghici S:
Recent additions and improvements to the Onto-Tools.
Nucleic Acids Res 2005:W762-765.
27. Onto-Express (OE) software   [http://vortex.cs.wayne.edu/
Projects.htm#Onto-Express]
28. James L: Comparative genomic hybridization as a tool in
tumour cytogenetics.  J Pathol 1999, 187:385-395.
29. Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S, Mechtershe-
imer G, Trumper L, Moller P, Lichter P, Barth TF: Classical Hodg-
kin lymphoma is characterized by recurrent copy number
gains of the short arm of chromosome 2.  Blood 2002,
99(2):1381-1387.
30. Weber-Matthiesen K, Deerberg J, Poetsch M, Grote W, Schlegel-
berger B: Numerical chromosome aberrations are present
within the CD30+ Hodgkin and Reed-Sternberg cells in 100%
of analyzed cases of Hodgkin's disease.  Blood 1995,
86(4):1464-1468.
31. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegel-
berger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, et al.:
Recurrent involvement of the REL and BCL11A loci in clas-
sical Hodgkin lymphoma.  Blood 2002, 99(4):1474-1477.
32. Kluiver J, Kok K, Pfeil I, de Jong D, Blokzijl T, Harms G, van der Vlies
P, Diepstra A, Atayar C, Poppema S, et al.: Golobal correlation of
genome and transcriptome changes in classical Hodgkin
lymphoma.  Hematol Oncol 2006, 25(1):21-29.
33. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T,
Bellas C, Castano A, Diez A, Flores T, et al.: Hodgkin and Reed-
Sternberg cells harbor alterations in the major tumor sup-
pressor pathways and cell-cycle checkpoints: analyses using
tissue microarrays.  Blood 2003, 101(2):681-689.
34. Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M,
Piris MA: p14(ARF) nuclear overexpression in aggressive B-
cell lymphomas is a sensor of malfunction of the common
tumor suppressor pathways.  Blood 2002, 99(4):1411-1418.
35. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Ber-
man K, Cobb MH: Mitogen-activated protein (MAP) kinase
pathways: regulation and physiological functions.  Endocr Rev
2001, 22(2):153-183.
36. Gutkind JS: Regulation of mitogen-activated protein kinase
signaling networks by G protein-coupled receptors.  Sci STKE
2000, 2000(40):RE1.
37. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey
JN, Carbone A, Younes A: MEK/ERK pathway is aberrantly
active in Hodgkin disease: a signaling pathway shared by
CD30, CD40, and RANK that regulates cell proliferation and
survival.  Blood 2003, 102(3):1019-1027.
38. Engstrom K, Willen H, Kabjorn-Gustafsson C, Andersson C, Olsson
M, Goransson M, Jarnum S, Olofsson A, Warnhammar E, Aman P:
The myxoid/round cell liposarcoma fusion oncogene FUS-
DDIT3 and the normal DDIT3 induce a liposarcoma pheno-
type in transfected human fibrosarcoma cells.  Am J Pathol
2006, 168(5):1642-1653.
39. Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman
P: Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces
C/EBP beta-mediated interleukin 6 expression.  Int J Cancer
2005, 115(4):556-560.
40. Hewitt KJ, Agarwal R, Morin PJ: The claudin gene family: expres-
sion in normal and neoplastic tissues.  BMC Cancer 2006, 6:186.
41. Shuai K: The STAT family of proteins in cytokine signaling.
Prog Biophys Mol Biol 1999, 71(3–4):405-422.
42. Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B,
Kussebi N, Lauber K, Wesselborg S, Loffler D, Horn F, et al.: STAT3
is essential for Hodgkin lymphoma cell proliferation and is a
target of tyrphostin AG17 which confers sensitization for
apoptosis.  Leukemia 2005, 19(6):936-944.
43. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U,
Mak TW: Signal transducer and activator of transcription 6 is
frequently activated in Hodgkin and Reed-Sternberg cells of
Hodgkin lymphoma.  Blood 2002, 99(2):618-626.
44. Ihle JN: The Stat family in cytokine signaling.  Curr Opin Cell Biol
2001, 13(2):211-217.
45. Bromberg J, Darnell JEJ: The role of STATs in transcriptional
control and their impact on cellular function.  Oncogene 2000,
19(21):2468-2473.
46. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, A
R: STAT proteins: from normal control of cellular events to
tumorigenesis.  J Cell Physiol 2003, 197(2):157-168.
47. Cochet O, Frelin C, Peyron JF, Imbert V: Constitutive activation
of STAT proteins in the HDLM-2 and L540 Hodgkin lym-
phoma-derived cell lines supports cell survival.  Cell Signal
2006, 18(4):449-455.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2008, 7:2 http://www.molecular-cancer.com/content/7/1/2
Page 13 of 13
(page number not for citation purposes)
48. Wang Y, Li G: ING3 promotes UV-induced apoptosis via Fas/
caspase-8 pathway in melanoma cells.  J Biol Chem 2006,
281(17):11887-11893.
49. Watson SK, deLeeuw RJ, Ishkanian AS, Malloff CA, Lam WL: Meth-
ods for high throughput validation of amplified fragment
pools of BAC DNA for constructing high resolution CGH
arrays.  BMC Genomics 2004, 5(1):6.
50. de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ,
Staudt LM, Martinez-Climent JA, Lam WL: Comprehensive whole
genome array CGH profiling of mantle cell lymphoma
model genomes.  Hum Mol Genet 2004, 13(17):1827-1837.
51. Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman
DE, MacAulay C, Ng RT, Brown CJ, Eichler EE, Lam WL: A compre-
hensive analysis of common copy-number variations in the
human genome.  Am J Hum Genet 2007, 80(1):91-104.
52. Khojasteh M, Lam WL, Ward RK, MacAulay C: A stepwise frame-
work for the normalization of array CGH data.  BMC Bioinfor-
matics 2005, 6:274.
53. Brown LA, Huntsman D: Fluorescent in situ hybridization on
tissue microarrays: challenges and solutions.  J Mol Histol 2007,
38(2):151-7.
54. Franke S, Wlodarska I, Maes B, Vandenberghe P, Delabie J, Hagemei-
jer A, De Wolf-Peeters C: Lymphocyte predominance Hodgkin
disease is characterized by recurrent genomic imbalances.
Blood 2001, 97(6):1845-1853.
55. Falzetti D, Crescenzi B, Matteuci C, Falini B, Martelli MF, Van Den
Berghe H, Mecucci C: Genomic instability and recurrent break-
points are main cytogenetic findings in Hodgkin's disease.
Haematologica 1999, 84(4):298-305.